LYPD5

Across TCGA pan-cancer cohorts, LYPD5 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated LYPD5 data layer compared with 23 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in mesothelioma (MESO), where higher LYPD5 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated LYPD5 expression acts as an unfavorable survival marker.

MESO and PRAD are the cancer types where LYPD5 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	DFS	Median	III,IV	0.078	0.376	.012	9	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

LYPD5–MESO (DFS)

Open the MESO breakdown →